Solventum (SOLV) Projected to Post Earnings on Tuesday

Key Points

• Solventum will report Q1 2026 results after the market close on Tuesday, May 5, 2026 at 4:30 PM ET, with analysts projecting $1.35 EPS and $1.9664 billion in revenue and the company guiding FY2026 EPS to 6.40–6.60.
• In the prior quarter Solventum beat estimates with $1.57 EPS on $2.0 billion revenue, posting a net margin of 18.69% and ROE of 25.26%, though revenue was down 3.7% year‑over‑year.
• SOLV traded down to about $67.84 (mid‑day) with a market cap of $11.76 billion and a P/E of 7.65; insider Director Amy McBride Wendell purchased 1,475 shares and several institutions have recently adjusted stakes.

Solventum (NYSE:SOLV - Get Free Report) will likely be posting its Q1 2026 results after the market closes on Tuesday, May 5th. Analysts expect Solventum to post earnings of $1.35 per share and revenue of $1.9664 billion for the quarter. Solventum has set its FY 2026 guidance at 6.400-6.600 EPS. Individuals may visit the the company's upcoming Q1 2026 earning results page for the latest details on the call scheduled for Tuesday, May 5, 2026 at 4:30 PM ET.

Solventum (NYSE:SOLV - Get Free Report) last issued its earnings results on Thursday, February 26th. The company reported $1.57 EPS for the quarter, topping analysts' consensus estimates of $1.50 by $0.07. The business had revenue of $2 billion for the quarter, compared to the consensus estimate of $1.96 billion. Solventum had a net margin of 18.69% and a return on equity of 25.26%. The company's revenue for the quarter was down 3.7% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.41 EPS. On average, analysts expect Solventum to post $7 EPS for the current fiscal year and $7 EPS for the next fiscal year.

Solventum Trading Down 2.8%

SOLV stock traded down $1.94 during mid-day trading on Tuesday, reaching $67.84. The company had a trading volume of 326,733 shares, compared to its average volume of 1,186,748. The company has a debt-to-equity ratio of 1.00, a current ratio of 1.23 and a quick ratio of 0.89. The company has a market capitalization of $11.76 billion, a PE ratio of 7.65, a price-to-earnings-growth ratio of 1.12 and a beta of 0.71. The firm has a 50 day moving average of $68.40 and a 200 day moving average of $74.61. Solventum has a 12 month low of $62.38 and a 12 month high of $88.20.

Insiders Place Their Bets

In other news, Director Amy Mcbride Wendell bought 1,475 shares of the stock in a transaction on Tuesday, March 10th. The stock was bought at an average cost of $68.03 per share, for a total transaction of $100,344.25. Following the completion of the purchase, the director directly owned 5,039 shares in the company, valued at approximately $342,803.17. The trade was a 41.39% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 0.24% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Solventum

Several institutional investors have recently bought and sold shares of SOLV. United Services Automobile Association acquired a new stake in Solventum in the first quarter valued at approximately $239,000. Woodline Partners LP boosted its stake in Solventum by 40.7% in the first quarter. Woodline Partners LP now owns 11,677 shares of the company's stock valued at $888,000 after acquiring an additional 3,377 shares in the last quarter. Intech Investment Management LLC boosted its stake in Solventum by 167.0% in the first quarter. Intech Investment Management LLC now owns 16,669 shares of the company's stock valued at $1,268,000 after acquiring an additional 10,425 shares in the last quarter. First Trust Advisors LP boosted its stake in Solventum by 5.8% in the second quarter. First Trust Advisors LP now owns 257,727 shares of the company's stock valued at $19,546,000 after acquiring an additional 14,151 shares in the last quarter. Finally, Marshall Wace LLP acquired a new stake in Solventum in the second quarter valued at approximately $766,000.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on SOLV. Weiss Ratings reiterated a "hold (c)" rating on shares of Solventum in a research note on Tuesday, January 27th. Stifel Nicolaus increased their price objective on shares of Solventum from $88.00 to $105.00 and gave the company a "buy" rating in a research note on Wednesday, January 7th. KeyCorp dropped their price objective on shares of Solventum from $99.00 to $92.00 and set an "overweight" rating on the stock in a research note on Monday. Piper Sandler dropped their price objective on shares of Solventum from $98.00 to $92.00 and set an "overweight" rating on the stock in a research note on Friday, April 17th. Finally, Wells Fargo & Company upgraded shares of Solventum to a "hold" rating in a research note on Wednesday, March 18th. Seven research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Solventum has an average rating of "Hold" and an average price target of $89.45.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.